COMP <GO>
LONA vs CRBU // REVENUE GROWTH (YOY)
LeonaBio Inc. (NASDAQ) VS. Caribou Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: LONA 1
— CRBU 2
■ METRIC PARITY
LAST: $4.94 (+0.61%) • MKT CAP: $46.3M
revenue-growth
—
LAST: $0.42 (-4.90%) • MKT CAP: $47.7M
revenue-growth
11.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LONA VS. CRBU)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LONA | CRBU | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | — | 11.70% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 4/9 | -2.00 | CRBU | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.4 | 27.5 | +15.90 | LONA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $46.3M | $47.7M | -$1.4M | CRBU | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LONA REV | CRBU REV | LONA GROSS % | CRBU GROSS % | LONA FCF | CRBU FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $11.2M | — | — | -$45.7M | -$112.4M |
| FY 2024 | $0 | $10.0M | — | — | -$97.2M | -$143.1M |
| FY 2023 | $0 | $34.5M | — | — | -$100.8M | -$93.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LONA // BETA —
CRBU // BETA —